Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies

Fig. 3

Lung function endpoints at week 24. Change from baseline in morning pre-dose trough FEV1 (a) and peak change from baseline in FEV1 within 2 h post-dose (b) (ITT population of the individual and pooled studies). Data are least squares mean treatment differences (95% confidence intervals) shown in mL. p < 0.0001 for all comparisons except for trough FEV1 in PINNACLE-2, GFF MDI versus GP MDI (p = 0.0003) and FF MDI (p = 0.0002). Data for PINNACLE-1, -2, and -4 studies have been published previously [7, 9]. FEV1, forced expiratory volume in 1 s; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; MDI, metered dose inhaler

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us